Administration of anti-IL-1 treatments, in mouse models, have similar effects reducing osteoclastic bone resorption and recruiting anti-tumour immune cells into the bone environment resulting in metastatic outgrowth being almost eliminated in bone [4], [5], [7], [8], [9]. The gene discussed is IL1A; the disease is neoplasm.